Scarica l'app Stockscreener
2.20
1.35%
-0.03
Precedente Chiudi:
$2.23
Aprire:
$2.19
Volume 24 ore:
117.27K
Relative Volume:
0.09
Capitalizzazione di mercato:
$20.44M
Reddito:
-
Utile/perdita netta:
$-45.57M
Rapporto P/E:
-0.3492
EPS:
-6.3
Flusso di cassa netto:
$-38.56M
1 W Prestazione:
-1.35%
1M Prestazione:
-14.73%
6M Prestazione:
+6.80%
1 anno Prestazione:
-18.82%
Intervallo 1D:
$2.13
$2.2575
Intervallo di 1 settimana:
$2.1201
$2.3929
Portata 52W:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Confronta SABS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.20 | 20.34M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedFree Trade Timing Strategy With Technical Data - Newser
Can swing trading help recover from SAB Biotherapeutics Inc. Equity Warrant lossesCapital Growth Plan for New Investors - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe chartsCapital Growth Plan for New Investors - Newser
SAB Biotherapeutics Inc. Equity Warrant stock retracement – recovery analysisShort Term Momentum Based Trading Strategy - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedPredictable Return Strategy with AI Support - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantLong-Term Signal Tracking and Profit Summary - Newser
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyFree Triple Digit Return Stock Predictions - Newser
SAB Biotherapeutics Inc. stock volume spike explainedMinimal Risk Growth Investment Opportunity Analysis - Newser
Chardan Capital Issues Pessimistic Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price - Defense World
Will SAB Biotherapeutics Inc. stock benefit from interest rate changesFree Trade Timing Strategy With Technical Data - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesFree Short Term Trading Opportunity Watch - Newser
SAB Biotherapeutics Inc. stock chart pattern explainedAI Trend Detection for Entry Timing - Newser
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Technical analysis overview for SAB Biotherapeutics Inc. stockDaily Pick Forecast with Entry Zones - Newser
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowLong-Term Investment Strategy Summary Guide - Newser
What the charts say about SAB Biotherapeutics Inc. todayValue Holding Return Summary With Outlook - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stockPredictable Income Summary for Long-Term Trades - Newser
Is SAB Biotherapeutics Inc. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis InsideMulti-Bagger Detection with Trend Tools - Newser
Top chart patterns to watch in SAB Biotherapeutics Inc.Daily Market Momentum Summary and Strategy - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionLow Risk Strategy with Smart Entry Zones - Newser
Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20 - Investing.com Canada
SAB Biotherapeutics 2024 Q4 Earnings Significant Loss Widening Despite Revenue Decline - AInvest
What high frequency data says about SAB Biotherapeutics Inc. Equity WarrantDownside Risk Evaluation and Stock Analysis - Newser
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost - TipRanks
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics Secures $175M Funding, Paving Way for Phase 2b Diabetes Trial and Justifying Buy Rating - TipRanks
SAB Biotherapeutics Expected to Beat Earnings Estimates Ahead of Q2 Release. - AInvest
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year - TipRanks
SAB Bio reports strong cash position with completed financing extending operational runway - MarketScreener
SAB BIO raises $175 mln, extends runway to mid-2028, initiates Phase 2b study in Q3 2025 - AInvest
SAB Biotherapeutics, Inc. SEC 10-Q Report - TradingView
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewswire
SAB Bio Lands Massive $175M Investment from Sanofi for Revolutionary Type 1 Diabetes Treatment - Stock Titan
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Gain Forecast with Momentum Indicators - Newser
SAB BIO Raises $175 Million in Oversubscribed Private Placement - Global Legal Chronicle
SAB Biotherapeutics Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
SAB Biotherapeutics Inc. Could See a Relief Rally From SupportRisk Controlled Short Term Trade Plans Published - beatles.ru
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. stockAchieve rapid financial growth with smart picks - Jammu Links News
What are the technical indicators suggesting about SAB Biotherapeutics Inc.Unmatched profit growth - Jammu Links News
Live Scanner Shows Breakout on SAB Biotherapeutics Inc. Equity WarrantWatchlist for Low Risk High Return Stocks Updated - metal.it
What institutional investors are buying SAB Biotherapeutics Inc. Equity Warrant stockUnlock powerful trading strategies for gains - Jammu Links News
Is SAB Biotherapeutics Inc. stock overvalued or undervaluedSkyrocketing returns - Jammu Links News
SAB Biotherapeutics Inc. Stock Analysis and ForecastFree Expert Stock Watchlist - Jammu Links News
What institutional investors are buying SAB Biotherapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
Is SAB Biotherapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - Jammu Links News
When is SAB Biotherapeutics Inc. stock expected to show significant growthBoost your returns with professional guidance - Jammu Links News
What are analysts’ price targets for SAB Biotherapeutics Inc. in the next 12 monthsBuild a portfolio with strong long-term growth - Jammu Links News
Published on: 2025-08-03 17:18:17 - Jammu Links News
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. Equity Warrant stockInvest smarter with advanced market data - Jammu Links News
What high frequency data says about SAB Biotherapeutics Inc.Momentum-Based Prediction for Quick Returns - Newser
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):